Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Ara Sadaniantz

Cardiovascular Disease Providence, RI Medical Doctor

NPI 1992766679 CMS profile 271657

One Randall Square, Suite 305, Providence, RI 02940

Open in the dashboard

General payments

$26,657

239 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Ara Sadaniantz of Providence, RI is reported in the CMS Open Payments database as having received $26,657 across 239 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $956 46
2020 General $6,017 85
2019 General $19,683 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ara Sadaniantz
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ara Sadaniantz were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ara Sadaniantz Cardiovascular Disease median Middle half National median
2019 $19,683 $450 $127–$1,392 $163
2020 $6,017 $242 $77–$751 $114
2021 $956 $335 $101–$1,037 $132
2022 $0 $395 $121–$1,211 $149
2023 $0 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Amgen Inc. $13,851 42 payments
  2. Janssen Pharmaceuticals, Inc $9,972 60 payments
  3. E.R. Squibb & Sons, L.L.C. $622 28 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $558 26 payments
  5. Amarin Pharma Inc. $435 24 payments
  6. Boston Scientific Corporation $184 8 payments
  7. AstraZeneca Pharmaceuticals LP $177 12 payments
  8. Novartis Pharmaceuticals Corporation $145 8 payments
  9. Medtronic Vascular, Inc. $129 2 payments
  10. Kowa Pharmaceuticals America, Inc. $123 9 payments
  11. Other $461 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,268 13 payments
  2. Food and Beverage $5,333 224 payments
  3. Travel and Lodging $43 1 payment
  4. Education $12 1 payment
Products named General payments · program years 2019–2021
  1. Repatha $13,851 42 payments
  2. XARELTO $9,972 60 payments
  3. ELIQUIS $622 28 payments
  4. JARDIANCE $537 25 payments
  5. PRADAXA $352 19 payments
  6. Vascepa $341 19 payments
  7. Corlanor $285 13 payments
  8. WATCHMAN $160 7 payments
  9. ENTRESTO $145 8 payments
  10. Bystolic $123 9 payments
  11. Other $1,092 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

239 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record